13,884 Shares in Moderna, Inc. $MRNA Acquired by Caprock Group LLC

Caprock Group LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 13,884 shares of the company’s stock, valued at approximately $334,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC increased its holdings in shares of Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares during the period. Atlantic Union Bankshares Corp purchased a new position in Moderna during the 2nd quarter worth $26,000. Whittier Trust Co. acquired a new position in Moderna in the second quarter valued at $28,000. MUFG Securities EMEA plc purchased a new stake in shares of Moderna in the second quarter valued at about $28,000. Finally, Assetmark Inc. boosted its stake in shares of Moderna by 137.7% during the second quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock worth $36,000 after buying an additional 752 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA accepted Moderna’s revised application and will initiate review of mRNA-1010 with an Aug. 5, 2026 PDUFA date; Moderna proposed an age‑based approval pathway (full approval for adults 50–64, accelerated approval for 65+) which could speed rollout for the 2026–27 flu season. Read More.
• Positive Sentiment: Market reaction: multiple outlets report a share pop after the review decision, reflecting investor optimism about near‑term commercial upside if approved. Read More.
• Positive Sentiment: Clinical pipeline momentum: a mid‑stage trial of a combo flu/COVID mRNA vaccine showed robust immune responses and no safety signals — supportive for Moderna’s broader respiratory vaccine strategy. Read More.
• Positive Sentiment: European expansion: the European Commission granted marketing authorization for Moderna’s COVID vaccine mNEXSPIKE, strengthening its respiratory portfolio in Europe. Read More.
• Neutral Sentiment: Analyst view: Goldman Sachs raised its price target to $41 but kept a “neutral” rating — a modest positive to guidance but still implies limited near‑term upside per that shop. Read More.
• Neutral Sentiment: Regulatory uncertainty remains: the FDA’s earlier refusal and the public debate around it show there is still execution risk and potential delays until the Aug. decision. Read More.
• Negative Sentiment: Legal risk: a court recently rejected two Moderna defenses in its patent dispute with Arbutus, keeping intellectual‑property exposure and potential liabilities on the table. Read More.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent research reports. Morgan Stanley set a $30.00 price target on Moderna in a research report on Monday. The Goldman Sachs Group boosted their target price on Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Tuesday. Evercore set a $35.00 price target on Moderna in a research note on Tuesday. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research report on Monday, January 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $31.47.

Insider Transactions at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 10.90% of the company’s stock.

Moderna Price Performance

Moderna stock opened at $46.60 on Thursday. The company has a market cap of $18.21 billion, a P/E ratio of -6.41 and a beta of 1.32. Moderna, Inc. has a one year low of $22.28 and a one year high of $55.20. The business has a fifty day moving average of $38.21 and a two-hundred day moving average of $30.15. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same quarter last year, the firm posted ($2.91) EPS. The business’s revenue was down 33.2% compared to the same quarter last year. As a group, analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.